IMMUNORNASE FUSIONS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 339

46. Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z.
(2008) The cytotoxic ribonuclease Onconase 1 targets RNA
interference (siRNA). Cell Cycle 7, 3258-3261.
47. Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub
RN, Chun H, et al. (2002) Phase II trial of a single weekly
intravenous dose of ranpirnase in patients with unresectable
malignant mesothelioma. J. Clin. Oncol. 20, 274-281.
48. Costanzi J, Sidransky D, Navon A, Goldsweig H. (2005)
Ribonucleases as a novel pro-apoptotic anticancer strategy:
review of the preclinical and clinical data for ranpirnase.
Cancer Invest. 23, 643-650.
49. Vogelzang NJ, Porta C, Mutti L. (2005) New agents in the
management of advanced mesothelioma. Semin. Oncol. 32,
336-350.
50. Pavlakis N, Vogelzang NJ. (2006) Ranpirnase—an antitumor
ribonuclease: its potential role in malignant mesothelioma.
Expert Opin. Biol. Ther. 6, 391-399.
51. Beck AK, Pass HI, Carbone M, Yang H, (2008) Ranpirnase as
a potential antitumor ribonuclease treatment for mesotheli-
oma and other malignancies. Future Oncol. 4, 341-349.
52. Halicka DH, Pozarowski P, Ita M, Ardelt W, Mikulski SM,
Shogen K, et al. (2002) Enhancement of activation-induced
apoptosis of lymphocytes by the cytotoxic ribonuclease
Onconase 1 (Ranpirnase). Int. J. Oncol. 21, 1245-1250.
53. Rybak SM, Saxena SK, Ackerman EJ, Youle RJ. (1991)
Cytotoxic potential of ribonuclease and ribonuclease hybrid
proteins. J. Biol. Chem. 266, 21202-21207.
54. Newton DL, Ilercil O, Laske DW, Oldfield E, Rybak SM,
Youle RJ. (1992) Cytotoxic ribonuclease chimeras: targeted
tumoricidal activity in vitro and in vivo. J. Biol. Chem. 267,
19572-19578.
55. Rybak SM, Newton DL, Mikulski SM, Viera A, Youle RJ.
(1993) Cytotoxic Onconase 1 and ribonuclease A chimeras:
comparison and in vitro characterization. Drug Deliv. 1, 3-10.
56. Rybak SM, Newton DL. (1999) Natural and engineered
cytotoxic ribonucleases:

63. Krauss J, Arndt MA, Dubel S, Rybak SM. (2008) Antibody-
targeted RNase fusion proteins (immunoRNases) for cancer
therapy. Curr. Pharm. Biotechnol. 9, 231-234.
64. Schirrmann T, Krauss J, Arndt MA, Rybak SM, Dubel S.
(2009) Targeted therapeutic RNases (ImmunoRNases).

Expert Opin. Biol. Ther. 9, 79-95.
65. Rybak SM, Arndt MA, Schirrmann T, Dubel S, Krauss J.
(2009) Ribonucleases and immunoRNases as anticancer
drugs. Curr. Pharm. Des. 15, 2665-2675.
66. De Lorenzo C, D'Alessio G. (2009) Human anti-ErbB2
immunoagents—immunoRNases and compact antibodies.
FEBS J. 276, 1527-1535.
67. Fang EF, Ng TB. (2010) Ribonucleases of different origins
with a wide spectrum of medicinal applications. Biochim.
Biophys. Acta 1815, 65-74.
68. Andrady C, Shrama SK, Chester KA. (2011) Antibody-
enzyme fusion proteins for cancer therapy. Immunotherapy
3, 193-211.
69. Durack DT, Ackerman SJ, Loegering DA, Gleich GJ. (1981)
Purification of human eosinophil-derived neurotoxin. Proc.
Natl. Acad. Sci. U S A 785165-5169.
70. Peterson CG, Venge P. (1983) Purification and characteriza-
tion of a new cationic protein--eosinophil protein-X (EPX)—
from granules of human eosinophils. Immunology 50, 19-26.
71. Rosenberg HF. (2008) Eosinophil-derived neurotoxin/RNase
2: connecting the past, the present and the future. Curr.
Pharm. Biotechnol. 9, 135-140.
72. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL,
Riordan JF, et al. (1985) Isolation and characterization of
angiogenin, an angiogenic protein from human carcinoma
cells. Biochemistry 24, 5480-5486.
73. Rosenberg HF. (2008) RNase A ribonucleases and host
defense: an evolving story. J. Leukoc. Biol. 83, 1079-1087.
74. Rybak SM, Hoogenboom HR, Meade HM, Raus JC,
Schwartz D, Youle RJ. (1992) Humanization of immunotox-
ins. Proc. Natl. Acad. Sci. U S A 89, 3165-3169.
75. Rybak SM, Hoogenboom HR, Newton DL, Raus JC, Youle
RJ. (1992) Rational immunotherapy with ribonuclease
chimeras: an approach toward humanizing immunotoxins.
Cell Biophys. 21, 121-138.
76. Hoogenboom HR, Raus JC, Volckaert G. (1990) Cloning and
expression of a chimeric antibody directed against the human
transferrin receptor. J. Immunol. 144, 3211-3217.
77. Newton DL, Nicholls PJ, Rybak SM, Youle RJ. (1994)
Expression and characterization of recombinant human eosi-
nophil-derived neurotoxin and eosinophil-derived neuro-
toxin-anti-transferrin receptor sFv. J. Biol. Chem. 269,
26739-26745.
78. Tai MS, Mudgett-Hunter M, Levinson D, Wu GM, Haber E,
Oppermann H, et al. (1990) A bifunction0al fusion protein
containing Fc-binding fragment B of staphylococcal protein
A amino terminal to antidigoxin single-chain Fv. Bio-
chemistry 29, 8024-8030.
79. Zewe M, Rybak SM, Dubel S, Coy JF, Welschof M, Newton
DL, et al. (1997) Cloning and cytotoxicity of a human pancre-
atic RNase immunofusion. Immunotechnology 3127-136.

therapeutic potential. Exp. Cell

Res. 253, 325-335.
57. Rybak SM. (2008) Antibody-Onconase 1 conjugates: cyto-
toxicity and intracellular routing. Curr. Pharm. Biotech. 9,
226-230.
58. Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM,
Rybak SM. (2001) Potent and specific antitumor effects of
an anti-CD22-targeted cytotoxic ribonuclease: potential for
the treatment of non-Hodgkin lymphoma. Blood 97, 528-535.
59. Newton DL, Hansen HJ, Liu H, Ruby D, Iordanov MS,
Magun BE, et al. (2001) Specifically targeting the CD22
receptor of human B-cell lymphomas with RNA damaging
agents. Crit. Rev. Oncol. Hematol. 39, 79-86.
60. De Lorenzo C, Nigro A, Piccoli R, D'Alessio G. (2002) A
new RNase-based immunoconjugate selectively cytotoxic for
ErbB2-overexpressing cells. FEBS Lett. 516, 208-212.
61. Schmidt SR. (2009) Fusion proteins as biopharmaceuticals—
applications and challenges. Curr. Opin. Drug. Discov. Devel.
12, 284-295.
62. Rybak SM, Newton DL, Xue Y. (1995) RNase and RNase
immunofusions for cancer therapy. Tumor Target. 1, 141-147.